About: The role of extracorporeal life support for patients with COVID‐19: Preliminary results from a statewide experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The role of extracorporeal life support for patients with COVID‐19: Preliminary results from a statewide experience Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The role of extracorporeal life support for patients with COVID‐19: Preliminary results from a statewide experience
Creator	Kilic, Arman Michael, \| Sanchez, Pablo Sultan, Ibrahim Dmitriy, \| Friscia, E Gnall, Eric Gutsche, Jacob Habertheuer, Andreas Hirose, Hitoshi Md, Zubkus Okusanya, Olugbenga Szeto, Y Usman, Asad Wilson, \|
source	Medline; PMC
abstract	OBJECTIVE: There is a paucity of clinical data on critically ill patients with COVID‐19 requiring extracorporeal life support. METHODS: A statewide multi‐institutional collaborative for COVID‐19 patients was utilized to obtain clinical data on the first 10 critically ill COVID‐19 patients who required extracorporeal membrane oxygenation (ECMO). RESULTS: Of the first 10 patients that required ECMO for COVID‐19, the age ranged from 31 to 62 years with the majority (70%) being men. Seven (70%) had comorbidities. The majority (80%) of patients had known sick contact and exposure to COVID‐19 positive patients or traveled to pandemic areas inside the United States within the 2 weeks before symptom onset. None of the patients were healthcare workers. The most common symptoms leading to the presentation were high fever ≥103°F (90%), cough (80%) and dyspnea (70%), followed by fatigue and gastrointestinal symptoms (both 30%), myalgia, loss of taste, pleuritic chest pain, and confusion (all 10%). All patients had bilateral infiltrates on chest X‐rays suggestive of interstitial viral pneumonia. All patients were cannulated in the venovenous configuration. Two (20%) patients were successfully liberated from ECMO support after 7 and 10 days, respectively, and one (10%) patient is currently on a weaning course. One patient (10%) died after 9 days on ECMO from multiorgan dysfunction. CONCLUSIONS: These preliminary multi‐institutional data from a statewide collaborative offer insight into the clinical characteristics of the first 10 patients requiring ECMO for COVID‐19 and their initial clinical course. Greater morbidity and mortality is likely to be seen in these critically ill patients with longer follow‐up.
has issue date	2020-04-25(xsd:dateTime)
bibo:doi	10.1111/jocs.14583
bibo:pmid	32333431
has license	no-cc
sha1sum (hex)	90a5cd368679312c69ac28163c8351c98efd224c
schema:url	https://doi.org/10.1111/jocs.14583
resource representing a document's title	The role of extracorporeal life support for patients with COVID‐19: Preliminary results from a statewide experience
has PubMed Central identifier	PMC7267409
has PubMed identifier	32333431
schema:publication	J Card Surg
resource representing a document's body	covid:90a5cd368679312c69ac28163c8351c98efd224c#body_text
is schema:about of	covid:arg/90a5cd368679312c69ac28163c8351c98efd224c named entity 'critically ill patients' named entity 'extracorporeal life support' named entity 'COVID-19' named entity 'IL-6' named entity 'COVID-19 outbreak' named entity 'conflict of interests' named entity 'ECMO' named entity 'hemorrhage' named entity 'Ebola' named entity 'ECMO' named entity 'ICU' named entity 'ECMO' named entity 'antiviral' named entity 'weaning' named entity 'remdesivir' named entity 'antiviral' named entity 'ECMO' named entity 'ECMO' named entity 'ECMO' named entity 'ECMO' named entity 'COVID' named entity 'critical care' named entity 'hydroxychloroquine' named entity 'immunosuppressive' named entity 'infectious disease outbreaks' named entity 'case series' named entity 'lung' named entity 'thrombosis' named entity 'COVID-19 pandemic' named entity 'infectious diseases' named entity 'malaria' named entity 'cytokine storm' named entity 'highly specialized' named entity 'evidence-based' named entity 'North America' named entity 'ECMO' named entity 'critically ill' named entity 'Preliminary results' named entity 'extracorporeal life support' named entity 'data' named entity 'patients' named entity 'life support' named entity 'extracorporeal' named entity 'life support' named entity 'patients' named entity 'COVID-19' named entity 'Preliminary' named entity 'extracorporeal' nodeID://b56509458 nodeID://b56529878 nodeID://b56618106 nodeID://b56757862 nodeID://b56761618 nodeID://b56979570 nodeID://b57080778 nodeID://b57169438 nodeID://b57169466 nodeID://b57237978 nodeID://b57260290 nodeID://b57576378 nodeID://b57586746 nodeID://b57618618 nodeID://b57631614 nodeID://b57926606 nodeID://b57926622 nodeID://b58042166

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software